In short
Cefiderocol is a novel siderophore cephalosporin antibiotic developed for treating infections caused by Gram-negative bacteria, including those resistant to other antibiotics. This article summarizes key information from clinical trials evaluating cefiderocol's effectiveness and safety for various types of infections.
At a glance
- Drug Name
- Cefiderocol (also known as S-649266, FETROJA®)
- Drug Class
- Siderophore cephalosporin antibiotic
- Target Pathogens
- Gram-negative bacteria, including carbapenem-resistant strains
- Indications Studied
- Complicated urinary tract infections, hospital-acquired pneumonia, ventilator-associated pneumonia, healthcare-associated pneumonia
- Administration
- Intravenous infusion, typically 2g every 8 hours (dose adjustments for renal function)
- Efficacy
- Comparable to standard-of-care antibiotics in clinical trials
- Safety Profile
- Generally well-tolerated; common side effects include gastrointestinal symptoms
- Special Populations
- Studies ongoing in patients with renal impairment, on ECMO, and with cystic fibrosis
- Potential Advantages
- Active against multidrug-resistant pathogens, novel mechanism of action
What is Cefiderocol?
Cefiderocol is a new type of antibiotic developed to treat serious infections caused by Gram-negative bacteria. It's also known by the brand name FETROJA® and was previously called S-649266 during its development. Cefiderocol belongs to a class of antibiotics called cephalosporins, but it has a unique feature that makes it effective against bacteria that are resistant to other antibiotics.
How Does Cefiderocol Work?
Cefiderocol uses a special mechanism to enter bacteria cells. It acts like a "Trojan horse" by attaching to iron molecules, which bacteria need to survive. This allows cefiderocol to sneak past the bacteria's defenses and enter the cell. Once inside, it kills the bacteria by preventing them from building their cell walls properly. This unique method makes cefiderocol effective against many types of bacteria, including those that have become resistant to other antibiotics.
What Conditions Does Cefiderocol Treat?
Cefiderocol is approved to treat several types of serious bacterial infections, including:
- Complicated urinary tract infections (cUTIs): These are infections in the urinary system that are more difficult to treat, often involving the kidneys (also called pyelonephritis).
- Hospital-acquired bacterial pneumonia (HABP): This is a lung infection that patients get while in the hospital.
- Ventilator-associated bacterial pneumonia (VABP): This is a type of pneumonia that occurs in patients who are on breathing machines.
- Healthcare-associated bacterial pneumonia (HCABP): This is pneumonia that develops in people who have frequent contact with healthcare settings.
Cefiderocol is particularly useful for treating infections caused by bacteria that are resistant to many other antibiotics, including a group called carbapenem-resistant bacteria.
Clinical Studies on Cefiderocol
Several clinical trials have been conducted to test the effectiveness and safety of cefiderocol:
- A study compared cefiderocol to another antibiotic called imipenem/cilastatin for treating complicated urinary tract infections. The study looked at how well the drug eliminated bacteria and improved symptoms.
- Another study compared cefiderocol to meropenem (another antibiotic) for treating hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia. This study primarily looked at survival rates of patients 14 days after starting treatment.
- A study called PERSEUS is examining how cefiderocol is used in real-world settings to treat various Gram-negative infections.
Administration and Dosage
Cefiderocol is given as an intravenous infusion, which means it's administered directly into a vein. The typical dose is 2 grams every 8 hours, but this can vary depending on the patient's kidney function. The infusion usually takes about 3 hours to complete. The duration of treatment can range from 7 to 14 days, depending on the type and severity of the infection.
Safety and Side Effects
Like all medications, cefiderocol can cause side effects. In clinical trials, researchers carefully monitored patients for any adverse reactions. Common side effects may include diarrhea, nausea, and reactions at the infusion site. More serious side effects are possible but less common. It's important to note that the benefits of treating severe infections often outweigh the risks of side effects.
Ongoing Research
Research on cefiderocol is ongoing to better understand how it works in different patient groups and situations:
- A study is looking at how cefiderocol behaves in patients on extracorporeal membrane oxygenation (ECMO), a life support machine that oxygenates blood outside the body.
- Another study is examining how cefiderocol works in patients receiving continuous renal replacement therapy (CRRT), a type of dialysis for patients with kidney failure.
- Researchers are also studying cefiderocol in patients with cystic fibrosis who have lung infections.
- A study is investigating how cefiderocol interacts with another medication called midazolam.
- Another study is looking at how cefiderocol works when combined with a new drug called xeruborbactam.
These ongoing studies will help doctors better understand how to use cefiderocol effectively and safely in different types of patients and situations.